answer text |
<p>Comparisons of uptake of medicines between different countries with different health
systems are difficult and should be treated with caution. However, we are committed
to working with industry on this issue and share the ambition to maximise the appropriate
use of innovation in our system and tackle unwarranted variation in uptake. The Government
and industry are currently working together through a series of workshops that will
provide the foundation for the next medicines pricing scheme, and discussions around
uptake, adoption and metrics have been a feature of those early meetings.</p><p> </p><p>The
recent Government and partner bodies response to the Accelerated Access Review sets
out how we will work with industry and the health system to create a streamlined and
sophisticated approvals system so that cost-effective breakthrough products – be they
drugs, devices, digital or diagnostics – can get into the National Health Service
as fast as possible.</p>
|
|